Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors
1Sichuan University, West China Hospital of Stomatology, State Key Laboratory of Oral Disease , Chengdu, 610041 , China.
Introduction:
Wild-type p53 gene is an essential cancer suppressor gene which plays an important role in carcinogenesis and malignant progressions. The p53 gene family participates in almost all the key procedures of cancer biology, such as programmed cell death, angiogenesis, metabolism and epithelial-mesenchymal transition. The mutation or functional defects of the p53 gene family are detected in most of the solid malignant tumors, and the restoration of the p53 gene by adenovirus-mediated gene therapy becomes a promising treatment for cancer patients now.
Areas Covered:
In the present review, the potential therapeutic effects of recombinant adenovirus p53 rAd-p53 ( Gendicine ™) were reviewed to explore the biological mechanism underlying the adenovirus-mediated p53 gene therapy. Then, the key points of the drug administration were discussed, including the routes of administration, dosage calculation and treatment cycles, based on findings of the preclinical and clinical trials in order to establish a standard treatment for the p53 gene therapy.
Expert Opinion:
As an important part of the combined therapy for the cancer patients, the adenovirus-mediated p53 gene therapy was blossomed to be a promising treatment strategy. A new evaluation criteria and guideline for the gene therapy is urgently needed for the further clinical practice.
Insights
Adenovirus-mediated p53 gene therapy shows promise for cancer treatment by restoring the wild-type p53 tumor suppressor gene. This review explores its mechanisms, administration, and potential as a combined cancer therapy.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- The wild-type p53 gene is a critical tumor suppressor involved in cancer biology.
- p53 gene mutations are prevalent in many solid tumors.
- Adenovirus-mediated p53 gene therapy offers a potential treatment strategy.
Purpose of the Study:
- To review the therapeutic effects of recombinant adenovirus p53 (rAd-p53).
- To explore the biological mechanisms of adenovirus-mediated p53 gene therapy.
- To discuss key aspects of drug administration for p53 gene therapy.
Main Methods:
- Review of preclinical and clinical trial findings.
- Analysis of biological mechanisms of rAd-p53.
- Discussion of administration routes, dosage, and treatment cycles.
Main Results:
- Adenovirus-mediated p53 gene therapy is a promising strategy.
- rAd-p53 (Gendicine™) demonstrates potential therapeutic effects.
- Standardized treatment protocols require further development.
Conclusions:
- Adenovirus-mediated p53 gene therapy is a valuable component of combined cancer treatment.
- Further clinical practice necessitates new evaluation criteria and guidelines for gene therapy.
Related Concept Videos
02:23Abnormal Proliferation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
00:59Gene Therapy
01:23Negative Regulator Molecules